Sarilumab

Sarilumab
Monoclonal antibody
Type Whole antibody
Source Human
Target IL-6
Clinical data
Routes of
administration		 Subcutaneous injection
ATC code none
Legal status
Legal status
  • Investigational
Identifiers
CAS Number 1189541-98-7 N
ChemSpider none
KEGG D10161 N
Chemical and physical data
Formula C6388H9918N1718O1998S44
Molar mass 144.13 kg/mol
 NYesY (what is this?)  (verify)

Sarilumab is a human monoclonal antibody against the interleukin-6 receptor.[1]

Regeneron and Sanofi are currently co-developing the drug for the treatment of rheumatoid arthritis (RA), for which it is in phase III trials.

Development in ankylosing spondylitis has been suspended after the drug failed to show clinical benefit over methotrexate in a phase II trial.[2]

Clinical trials

Rheumatoid arthritis

On May 15, 2013, both companies announced that 2 new trials were starting (COMPARE and ASCERTAIN) and the first patients had already been enrolled.[3]

In June 2015 a phase 3 trial (with methotrexate) for RA reported meeting its 3 coprimary endpoints.[4]

In Nov 2015 the SARIL-RA-TARGET trial reported good results (meeting both its coprimary end points).[5]

In Nov 2016 the MONARCH phase III trial comparing sarilimab to adalimumab (an anti-TNF) found sarilumab superior as a monotherapy for RA.[6]

History

In October 2016 the US FDA refused approval (for RA) due to GMP violations.[6]

Side effects of subcutaneous sarilumab

At 200 mg every 2 weeks, 13.6% of patients had neutropenia in one trial.[6]

See also

References

  1. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Sarilumab" (PDF). American Medical Association. Needs subscription
  2. ↑ Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis. July 2011
  3. ↑ Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA). May 2013
  4. ↑ "Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study.". Arthritis Rheumatol. 67 (6): 1424–37. 2015. doi:10.1002/art.39093. PMID 25733246.
  5. ↑ Sarilumab effective in broad range of RA patients: Study
  6. 1 2 3 IL-6 Blocker Beats Anti-TNF in RA. Nov 2016


This article is issued from Wikipedia - version of the 11/24/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.